
    
      An open label multicentric Phase 1 study of HEC68498 in patients with advanced refractory
      solid tumors.The study will follow a 3+3 design until significant toxicity as described in
      the protocol and considering pharmacokinetics of the study drug determined from cohorts.
    
  